CardioSignal by Precordior
CardioSignal by Precordior is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at CardioSignal by Precordior.
CardioSignal by Precordior is a company.
Key people at CardioSignal by Precordior.
CardioSignal, developed by Precordior, is a medical-grade smartphone app that detects atrial fibrillation (AFib) using gyrocardiography to analyze chest micro-motions via a phone's built-in sensors—no additional hardware needed. Users simply lie down, place the phone on their chest for one minute, and receive instant results with 95-96% accuracy.[1][2][4][6] It serves healthcare providers, primary care doctors, remote patient monitoring programs, and at-risk populations, solving the problem of late heart disease detection amid cardiology bottlenecks in hospitals by enabling scalable, low-cost screening for AFib, with upcoming expansions to heart failure (HF) and coronary artery disease (CAD).[1][2][3][5] Precordior, founded in 2016 in Turku, Finland, has raised $12.19M, holds 24 granted patents (plus 30+ pending), and achieved CE IIa certification in Europe while entering the US market in 2023 via FDA collaborations and partnerships like Mayo Clinic.[1][2][3][4]
The company shows strong growth momentum, including a $10M funding round in 2021 from investors like Maki.vc, wins like the American Heart Association grant, and board additions such as Ursula Burns (ex-Xerox CEO).[3][4] Projections from 2021 aimed for 1.27M daily users and €85M revenue by 2025 across EU, US, and China, driven by B2B sales to pharma (e.g., Roche, Novartis trials) and healthcare firms.[5]
Precordior spun out from the University of Turku in Finland in 2016 as an academic venture, building on over a decade of research in gyrocardiography—a technique using smartphone accelerometers and gyroscopes to measure heart-induced chest vibrations.[1][3][4][6] The idea emerged from cardiologists and technologists addressing unmet needs in early cardiac detection, starting with AFib, which causes millions of deaths yearly due to undetected cases.[5][6] Key figures include CEO Juuso Blomster, a cardiologist leading product vision.[4]
Early traction came from clinical validation: the V1 AFib app was proven effective, securing 19 patents initially (now 24+), EU Seal of Excellence, and CE IIa approval.[1][2][5][6] Pivotal moments include 2021's $10M funding, 2022 US entry announcements with AHA grant and Mayo Clinic acceptance, and 2023 FDA-aligned launches for remote care.[3][4]
CardioSignal rides the digital health and remote monitoring wave, accelerated by post-COVID demand for non-invasive, at-home diagnostics amid 300M+ EU and 1B global at-risk users for €4.2B TAM.[3][5][6] Timing aligns with smartphone ubiquity, AI-driven biomarker analysis, and cardiology overload—80% of CVD deaths from undetected heart attacks/strokes make early, scalable tools critical.[5] Market forces like aging populations, pharma's precision medicine push, and regulatory nods (FDA, CE) favor it, positioning Precordior to democratize cardiac care for underserved groups via population screening and point-of-care.[3][5]
It influences the ecosystem by pioneering gyrocardiography, inspiring sensor-based medtech, and fostering university-hospital trials that validate multi-disease detection under one app—potentially slashing costs versus ECGs or imaging.[1][4][6]
CardioSignal is poised to disrupt cardiac diagnostics by bundling AFib, HF, and CAD into a single smartphone platform, with US launches expanding from Europe's CE base to capture pharma contracts and population health deals. Near-term: FDA-cleared remote solutions by 2026, leveraging 2023 momentum for broader adoption.[3] Shaping trends include AI-enhanced sensors, telehealth integration, and global equity in heart care, evolving Precordior's influence toward a full cardiac suite leader—scaling from $12M raised to projected €85M revenue while saving lives through everyday tech.[1][5] This ties back to its core: turning smartphones into lifesaving tools for the world's top killer.
Key people at CardioSignal by Precordior.
